News

Verve Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More
Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...
Lock In The 81.5% Run - Initiating Verve With A Sell
Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...
Benzinga.com2d
5 Analysts Assess Verve Therapeutics: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...